When most people think about THC isomers, they think about variations in the double bond position — delta-8, delta-9, delta-10. But there is another axis of structural variation: stereochemistry. THC-C5 (cis-Δ) — also written Δ9-cis-THC — is the geometric isomer of standard Δ9-THC, differing not in which carbon bears the double bond but in the three-dimensional arrangement of atoms at the ring junction. It has the same molecular formula, the same pentyl side chain, and the same double bond position as standard trans-Δ9-THC. And yet a 2021 study found it in European fiber hemp at concentrations comparable to standard Δ9-THC — while being essentially undetectable in high-THC cannabis (Ujváry et al., 2021).
That finding has scientific, pharmacological, and regulatory implications that are still being worked out.
What Is THC-C5 (cis-Δ)?
The full name “tetrahydrocannabinol(−)-cis-Δ” encodes its key structural information. The “cis” refers to the stereochemical relationship at the two ring junction carbons — C-6a and C-10a — which in standard (−)-trans-Δ9-THC are positioned in a trans (opposite) configuration. In cis-Δ9-THC, those same two carbons are in a cis (same-side) configuration, giving the molecule a different overall three-dimensional shape. The “(−)” indicates its optical rotation (levorotatory), and “C5” specifies the standard pentyl (five-carbon) side chain (Ujváry et al., 2021).
This is not a homolog difference (no change in chain length), not a double bond positional difference, and not an acid/neutral difference — it is a purely stereochemical distinction at the ring junction, analogous to how cis and trans fatty acids differ.
Molecular Formula: C₂₁H₃₀O₂ (identical to Δ9-trans-THC)
Ring junction configuration: cis (6aS,10aR in major natural enantiomer)
Double bond: 9th carbon — same as standard Δ9-THC
Side chain: Pentyl (C5) — same as standard Δ9-THC
Major natural enantiomer: (−)-Δ9-cis-THC (6aS,10aR) — scalemic, ~80–90% ee
Natural occurrence: European fiber hemp; undetectable in high-THC cannabis
Psychoactive: Yes — partial CB1 agonist, but less potent than trans-Δ9-THC
First formally characterized in natural cannabis: Ujváry et al., 2021
The 2021 Study: Finding cis-THC Where No One Expected It
The formal identification, quantification, and pharmacological characterization of naturally occurring Δ9-cis-THC was published in 2021 in the Journal of Natural Products by Ujváry and colleagues. Their key findings were striking in several respects.
First, they confirmed cis-Δ9-THC is genuinely present in cannabis — specifically in European fiber hemp varieties registered for agricultural use — at concentrations comparable to those of (−)-trans-Δ9-THC in those varieties. In the same hemp samples, both the trans and cis forms co-occurred at similar levels.
Second, and perhaps more surprising: in high-THC medicinal cannabis, cis-Δ9-THC was essentially undetectable. The compound appears specifically associated with hemp chemotypes, not high-potency cannabis (Ujváry et al., 2021). The reasons for this strain-specific distribution are not fully understood — it may reflect differences in biosynthetic pathways, photochemical conversion rates, or other plant-chemistry factors that differ between hemp and high-THC varieties.
Third, the natural cis-THC found in hemp is not racemic — it is scalemic, meaning it has a specific enantiomeric excess of approximately 80–90% for the (−) enantiomer (6aS,10aR absolute configuration). This confirms it is a naturally produced chiral compound with a defined biological origin, not a racemic artifact of chemical degradation (Ujváry et al., 2021).
Pharmacology: Partial CB1 Agonist, Lower Potency Than trans-THC
Ujváry et al. (2021) characterized the major natural enantiomer (−)-Δ9-cis-THC in both in vitro receptor binding assays and in vivo behavioral testing:
In vitro, it was established as a partial cannabinoid receptor agonist — confirming CB1 activity, but indicating it does not fully activate the receptor the way standard (−)-trans-Δ9-THC does.
In vivo, (−)-Δ9-cis-THC elicited a full tetrad response in mice — the four-behavior cannabimimetic assay (hypothermia, catalepsy, hypolocomotion, and analgesia) used to assess CB1 agonism — but only at a dose of 50 mg/kg. Standard (−)-trans-Δ9-THC produces a full tetrad at considerably lower doses, demonstrating that the cis isomer is meaningfully less potent. The stereochemical difference at the ring junction reduces the compound’s fit within the CB1 binding pocket and consequently its ability to activate the receptor (Ujváry et al., 2021).
Additionally, Lewis acid isomerization studies showed that (+)-cis-THC — the opposite enantiomer — converts to (+)-Δ8-trans-THC, further confirming the structural interconvertibility of cis and trans THC forms under specific chemical conditions (Ujváry et al., 2021).
| Property | (−)-trans-Δ9-THC (standard) | (−)-cis-Δ9-THC (THC-C5 cis) |
|---|---|---|
| Ring junction configuration | trans (6aR,10aR) | cis (6aS,10aR) |
| Molecular formula | C₂₁H₃₀O₂ | C₂₁H₃₀O₂ (identical) |
| CB1 receptor activity | Partial agonist (high affinity) | Partial agonist (lower affinity/potency) |
| Psychoactive | Yes — primary psychoactive cannabinoid | Yes — but less potent |
| In vivo tetrad dose (mice) | Lower (standard reference dose) | 50 mg/kg to elicit response |
| Natural distribution | Abundant in high-THC cannabis | Hemp only; absent in high-THC cannabis |
| Enantiomeric purity (natural) | Essentially enantiopure (−) form | Scalemic (~80–90% (−) form) |
Regulatory Implications: A Genuine Challenge for Hemp Law
The presence of cis-Δ9-THC in hemp at meaningful concentrations creates a real problem for regulatory frameworks built around the concept of “Δ9-THC and its isomers.” If the legal THC limit for hemp is defined as 0.3% Δ9-THC and its isomers, then cis-Δ9-THC would appear to be captured by that definition — potentially making hemp that tests below 0.3% total Δ9-trans-THC but contains comparable levels of the cis isomer technically non-compliant.
Ujváry et al. (2021) explicitly flagged this issue, stating that the current legal framework for distinguishing narcotic from non-narcotic cannabis varieties “needs therefore revision, or at least a more specific interpretation” in light of the cis-THC findings. As of the time of writing, regulatory guidance on how to treat cis-Δ9-THC has not been uniformly established across jurisdictions.
How Does cis-THC Get Into Hemp?
The mechanism behind cis-Δ9-THC’s specific occurrence in hemp rather than high-THC cannabis is not definitively established. Possible explanations include photochemical conversion of trans-THCA or trans-THC to the cis form under UV light exposure — a known transformation for related cannabinoids including CBD and THCA. Another possibility is that the compound represents a minor enzymatic product of THCA synthase activity in hemp’s specific genetic background. The scalemic (not racemic) enantiomeric ratio of natural cis-THC strongly implies a biologically controlled rather than purely random chemical process (Ujváry et al., 2021).
Frequently Asked Questions
Is cis-THC the same as delta-9-THC?
They share the same molecular formula, double bond position, and side chain — but differ in the spatial arrangement of atoms at the ring junction (cis vs. trans configuration). This stereochemical difference produces measurably different CB1 receptor affinity and in vivo potency. cis-THC is less potent than standard trans-Δ9-THC at equivalent doses (Ujváry et al., 2021).
Is cis-THC psychoactive?
Yes — it is a partial CB1 agonist and produced a full tetrad response in mice, though at a substantially higher dose (50 mg/kg) than standard trans-Δ9-THC. The practical psychoactivity of the concentrations found in hemp is unclear, but the compound should not be assumed non-psychoactive simply because it is a geometric isomer of THC (Ujváry et al., 2021).
Why is cis-THC found in hemp but not high-THC cannabis?
This is not fully understood. The distribution may relate to differences in biosynthetic pathways, photochemical conversion rates under different growing conditions, or genetic differences in enzyme expression between hemp and high-THC varieties. The scalemic enantiomeric ratio of natural cis-THC suggests a biologically controlled origin rather than random chemical conversion (Ujváry et al., 2021).
Does cis-THC count toward hemp’s 0.3% THC limit?
Potentially yes — regulations in many jurisdictions define the threshold as Δ9-THC and its isomers. cis-Δ9-THC is an isomer of Δ9-THC by most definitions. Whether standard analytical lab tests used for hemp compliance specifically detect and report cis-THC separately from trans-THC depends on the method used. This remains an unresolved regulatory question (Ujváry et al., 2021).
The Bottom Line
THC-C5 (cis-Δ) is a genuine scientific surprise — a compound with the same molecular formula as standard Δ9-THC, found in notable concentrations specifically in hemp, with confirmed CB1 receptor activity and lower-but-real psychoactive potential. Its 2021 formal characterization by Ujváry et al. was the first rigorous study of naturally occurring cis-Δ9-THC and immediately raised questions that neither regulators nor the hemp industry had anticipated.
Its significance operates on two levels: scientifically, it demonstrates that cannabinoid pharmacology varies meaningfully with stereochemistry, not just side-chain length or double bond position. Regulatorily, it challenges the premise that low-THC hemp contains only negligible psychoactive THC — because the isomer definition may capture cis-THC alongside the trans form everyone was measuring for.
Nothing in this article constitutes medical advice. Always consult a qualified healthcare provider before making any decisions about supplementation or treatment.
References
- Ujváry, I., Grotenhermen, F., Rätsch, C., & Russo, E. (2021). Δ9-cis-Tetrahydrocannabinol: Natural occurrence, chirality, and pharmacology. Journal of Natural Products, 84(4), 1062–1074. https://doi.org/10.1021/acs.jnatprod.0c01156
